Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod

Companies Partnered Up In March 2020; Ryaltris Already Rolled-Out In Europe

Executive Summary

Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.

You may also be interested in...



Glenmark’s Ryaltris ‘Ahead Of The Game’ In Markets, COVID-19 Nasal Spray Coming

There is momentum for Glenmark’s Ryaltris across new launch markets internationally, with FY2023 and FY2024 seen as important years for revenue scale-up. A partnered nitric oxide nasal spray for COVID-19 faces trial recruitment challenges in India but the firm hopes to be able to debut the product this year.

Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals

Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.

Hikma Strikes Deal For Ryaltris In US

Hikma has struck a deal with Glenmark to gain US rights to its Ryaltris nasal spray. The agreement comes as Hikma reported sales ahead by 7% in 2019 on strong performances from the firm’s Injectables and Branded segments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel